

A brief review on features of falciparum malaria during pregnancy

Alexandre Manirakiza,¹
 Eugène Serdouma,²
 Richard Norbert Ngalé,²
 Sandrine Moussa,¹ Samuel Gondjé,³
 Rock Mbetid Degana,³
 Gislain Géraud Banthas Bata,³
 Jean Methode Moyen,³ Jean Delmont,⁴
 Gérard Grésengué,² Abdoulaye Sepou²

¹Pasteur Institute of Bangui, Bangui, Central African Republic; ²University of Bangui, Bangui, Central African Republic; ³Ministry of Public Health, Population and AIDS Control, Bangui, Central African Republic; ⁴Center for Training and Research in Tropical Medicine and Health, Faculty of Medicine North, Marseille, France

Abstract

Malaria in pregnancy is a serious public health problem in tropical areas. Frequently, the placenta is infected by accumulation of *Plasmodium falciparum*-infected erythrocytes in the intervillous space. Falciparum malaria acts during pregnancy by a range of mechanisms, and chronic or repeated infection and co-infections have insidious effects. The susceptibility of pregnant women to malaria is due to both immunological and humoral changes. Until a malaria vaccine becomes available, the deleterious effects of malaria in pregnancy can be avoided by protection against infection and prompt treatment with safe, effective antimalarial agents; however, concurrent infections such as with HIV and helminths during pregnancy are jeopardizing malaria control in sub-Saharan Africa.

Introduction

Malaria is the cause of significant morbidity and mortality worldwide. In 2015, an estimated 212 million cases of malaria occurred globally, with 429 000 deaths. Most cases occurred in tropical countries (90%), mainly among children under 5 years of age.¹ Most cases of malaria are caused by either *Plasmodium falciparum* or *P. vivax*, but almost all deaths are due to falciparum malaria.² Malaria can have devastating consequences on both the mother and the developing foetus. The effects of malaria in pregnancy, due to either *P. falciparum*

and *P. vivax*, include maternal anaemia, spontaneous miscarriage, stillbirth, preterm delivery and foetal growth retardation, which increase morbidity and mortality in infancy.³⁻⁶ In 2007, Dellicour and collaborators estimated that approximately 85 million pregnancies occurred in areas with *P. falciparum* transmission, 54.7 million of which were in areas with stable falciparum malaria, and 31 million were in Africa.⁷

The consequences of falciparum malaria during pregnancy are mediated through a number of mechanisms, and chronic or repeated infections and co-infections have insidious effects. The susceptibility of pregnant women to malaria is due to both immunological and humoral changes,^{8,9} on which research on a malaria vaccine are focused. The adverse effects of malaria in pregnancy vary geographically by malaria transmission intensity. This is thus an important preventable infection, and access to safe, effective antimalarial drugs remains essential. The aim of this study was to synthesise the empirical literature in order to obtain a comprehensive understanding of the pathophysiology, histology and immunology, clinical manifestation and epidemiological features of malaria during pregnancy and also effective antimalarial agents, prevention and co-infections in tropical areas of Africa. A literature search was performed to identify reports on malaria and pregnancy, comprising original research and systematic reviews. No restriction was set on time of publication, but only peer-reviewed publications in English in Medline and PubMed were accessed. The terms used were: malaria AND pregnancy OR malaria AND pregnant OR plasmodium AND pregnancy malaria AND pregnant AND pathophysiology OR histology OR immunology OR clinics OR epidemiology OR antimalarial OR prevention OR HIV AND/OR helminths. Articles were screened on the basis of title and abstract. The flow of retrieval is shown in Figure 1. Recommendations and health policy with regard to malaria during pregnancy were retrieved from the WHO library.

Pathophysiology and histology of placental malaria

P. falciparum can parasitise red blood cells (RBCs) and then adhere to the linings of small blood vessels, thus obstructing perfusion in organs including the heart, lung, brain, liver, kidney, subcutaneous tissues and placenta.^{10,11} Sequestration in the placenta is different from that in other organs, as the RBCs accumulate in the intervillous space¹² such that the parasite density is often higher than in peripheral blood.¹⁰ The sequestration allows parasite maturation on

Correspondence: Alexandre Manirakiza, Pasteur Institute of Bangui, Rue Pasteur, PO Box 923, Bangui, Central African Republic. E-mail: amanirak@yahoo.fr

Key words: Malaria; *Plasmodium falciparum*; pregnancy.

Acknowledgments: we are grateful to Professor Elisabeth Heseltine for editing this manuscript.

Contributions: the authors contributed equally.

Conflict of interests: the authors have no conflict of interests.

Received for publication: 24 March 2017.

Revision received: 16 August 2017.

Accepted for publication: 17 August 2017.

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

©Copyright A. Manirakiza et al., 2017
 Licensee PAGEPress, Italy
 Journal of Public Health in Africa 2017; 8:668
 doi:10.4081/jphia.2017.668

the placental endothelium, where mature trophozoites and schizonts are often observed.^{13,14} Sequestration is probably possible only from the fourth month of pregnancy, when the anatomical structures of the placenta are already formed.¹⁵ Lacunar formations in the trophoblast appear between the 10th and 21st day but do not contain maternal blood until the 12th week of pregnancy.^{15,16} The pathophysiological processes that cause adverse foetal effects of malaria in pregnancy are due mainly to accumulation of parasitised RBCs in placental intervillous spaces.

Histologically, inflammatory remodelling is characterized by infiltration of phagocytic cells (monocytes).¹⁷⁻²¹ Sequestration of infected erythrocytes in the placenta triggers beta-chemokine secretion by maternal mononuclear cells,²²⁻²⁴ and macrophages and monocytes, attracted by chemotaxis, predominate in the intervillous space, resulting in modification of the spiral microvessels.²⁵

These histological changes form a mechanical barrier that reduces intra-placental blood flow and may lead to foetal hypoxia.²⁶ The process has been suggested as a cause of intrauterine growth retardation and therefore low birth weight,²⁷⁻²⁹ although it may not be solely responsible,³⁰ as disturbance of the transport of nutrients into the placenta by inflammatory lesions may also play a role.³¹⁻³⁴

Placental malaria is determined either on stained slides prepared from placental blood or in stained placental biopsies, a much more sensitive method for detecting placental parasitaemia,³⁵ which can detect infections preceding delivery by up to one month by observation of the product of digestion of haemoglobin by the parasite - malaria pigment or haemozoin in histological sections. The pathological classification proposed for the phases of placental infestation¹⁸ is: i) no infection: parasites and malaria pigment absent; ii) acute infection: parasites present, malaria pigment absent; iii) chronic infection: parasites and malaria pigment present; and iv) past infection: no parasites, malaria pigment present.

Immunological changes related to malaria during pregnancy

Specific humoral immunity to malaria in pregnant women

All women are not equally susceptible to malaria. The frequency and severity of malaria are greater during a first pregnancy than in subsequent ones,^{36,37} and parasitaemia decreases with parity and maternal age.³⁸ People living in malaria-endemic areas who are repeatedly bitten by mosquitoes infected with *Plasmodium* develop a certain antigenic reaction and immunity due to immunoglobulins G (IgG), which targets surface antigens of infected erythrocytes known as variant surface antigens (VSAs), which are produced by the parasites. They are encoded by a number of genes, organized into multigene families in the parasite chromosomes, and are involved in the adhesion of infected mature erythrocytes (over 18 h after invasion) in the tissues. The gradual acquisition of partial immunity with repeated exposure to *P. falciparum*-infected mosquito bites (in areas where malaria transmission is stable and intense) is due mainly to acquisition of IgG directed against the most numerous VSAs present in the parasite population.^{39,40} In pregnant women, the VSA expressed by parasitised RBCs that mediate adhesion to chondroitin sulphate A (CSA) and hyaluronic acid on the syncytiotrophoblasts that line the placental intervillous spaces have unique antigenic properties;¹⁴ they are fundamentally different from the corresponding antigens expressed on the infected erythrocyte surface in nonplacental *P. falciparum* infections, and are the main target of IgG.^{9,41}

The parasite ligand that mediates adhesion of parasitised RBCs to CSA is a conserved antigen, the recognition of which requires a significant change in plasma IgG,⁴² which pointed to the existence of

pregnancy-specific VSAs (VSA_{PAM}).⁴³ The dominant VSA on the surface of parasitised RBCs is *P. falciparum* erythrocyte membrane protein 1 (PfEMP1), which is encoded by the *var2* multigene family.^{14,26} These VSA_{PAM} are also collectively referred to as VAR2CSA;^{14,26,44-46} other receptors could be involved.^{45,47} Several studies have demonstrated the integral role of VAR2CSA in placental malaria (reviewed in⁴⁸). The extracellular region of VAR2CSA includes an N-terminal sequence, six cysteine-rich Duffy binding-like domains and inter-domain regions that increasingly appear to play a key role in the adhesion and immunogenicity of recombinant VAR2CSA protein fragments.^{49,50}

In non-pregnant women and in men, the antibodies do not recognize VSA_{PAM},^{43,51} and women living in malaria-endemic areas during their first pregnancy do not yet have specific antibodies and are therefore highly susceptible to malaria infection. In subsequent pregnancies, exposure to VSA_{PAM} induces the production of specific IgG,^{42,43,52-54} which is detectable at 20 weeks in the first pregnancy but appears earlier and more rapidly in subsequent pregnancies, decreasing after childbirth.^{55,56} It has been shown experimentally that the


serum of multigravidae women exposed to *P. falciparum* malaria inhibits adhesion to CSA of infected erythrocytes from pregnant women, while no inhibition was observed with sera from primigravidae women in early pregnancy or from men.⁴²

Others immunological changes related to the susceptibility of pregnant women to malaria

Pregnancy is associated with decreased immunity. The high protein requirements associated with nutritional deficiency explain a failure of gamma-globulin production, and immunosuppression due to increased cortisol levels in maternal blood has also been proposed.⁵⁷⁻⁶⁰ The decrease in cellular immunity during pregnancy makes women susceptible to the infections that are usually controlled by this type of immunity,^{61,62} including malaria.⁶³ The frequency of malaria attacks and hyper-parasitaemia during pregnancy have been linked to the state of transient immunosuppression, while humoral immunity against malaria is not affected.^{64,65}

Clinical manifestations of malaria in pregnant women

In regions with high rates of transmis-



Documents accessed on other website like www.who.int are taken into account on this flow diagram

Figure 1. Flow diagram of the numbers of articles reviewed.

sion of malaria, women have considerable immunity to malaria by the time they reach child-bearing age. Nevertheless, they are susceptible to placental malaria during their first or second pregnancy and less so with subsequent pregnancies.⁶⁶ Pregnant women malaria infection more frequently have a higher density of parasites, more malaria episodes, anaemia, severe malaria and mortality. The negative effects on infants include low birth weight due to in utero growth retardation, premature birth, abortion, intrauterine death, neonatal mortality, infant mortality and congenital malaria. Some of the consequences of malaria in pregnancy were described at the beginning of the 20th century^{67,68} and then later.⁶⁹⁻⁷⁴ Malaria makes a normal pregnancy a pathological pregnancy,⁷⁵ although its effects manifest differently by gestational age.

Low birth weight and maternal anaemia are major public health problems. At national level, the indicators of malaria control for pregnant women are the percentage of children with a low birth weight and the percentage of women with anaemia during the third trimester of pregnancy.⁷⁶ Anaemia due to malaria in pregnant women is defined by a haemoglobin concentration ≤ 11 g/dL.⁷⁷ The syndrome is multifactorial, and its mechanism is still poorly understood but is due to both the destruction of infected and uninfected erythrocytes and inhibition of erythropoiesis. *P. falciparum* induces the production of mediators and inhibitors of erythroid precursors,⁷⁸⁻⁸⁰ such as macrophage migration inhibitory factor,⁸¹ which is increased in the placenta of infected pregnant women and leads to suppression of the formation of erythroid colonies. It acts synergistically with TNF- α and interferon- γ , which also inhibit haematopoiesis.⁸²

In endemic countries, a low birth weight is often associated with intrauterine growth retardation and premature delivery (<37 weeks of gestation).^{5,83,84} Malaria and high placental parasitaemia increase the risk for preterm delivery.⁸⁵⁻⁸⁷

Epidemiological features of malaria in pregnant women

It has long been recognized that the

clinical manifestations of malaria in a community are determined by the degree of endemicity of the infection in the local environment and by the age-specific levels of immunity acquired through exposure to infection.⁶⁵ Tables 1 and 2⁸⁸⁻¹⁰⁴ detail some of the prevalence of malaria in pregnant women in high-transmission and in lower-transmission areas are, respectively.

In areas of intense, stable transmission of *P. falciparum*, partial immunity leads to clinically latent malaria during pregnancy. Infection is suspected from maternal anaemia and a low-birth-weight infant.¹⁰⁵⁻¹⁰⁷ The best epidemiological indicator of malaria during pregnancy is the prevalence of placental infestation with *P. falciparum*.^{99,108} Nevertheless, the existence of a correlation between parasite load in peripheral blood and cord blood remains controversial. For example, Brabin and Rogerson¹⁰⁹ reported a correlation between these values, while Ismail and colleagues¹⁸ reported no parasitaemia in 69% of samples of peripheral blood but evidence of infection in placental samples. The differences in the results are due partly to geographical variations in malaria epidemiology and partly to the laboratory methods used. In a meta-analysis of 20 studies of peripheral blood and placental parasitaemia, 9% of placentas and none of the peripheral blood samples were infected.¹⁰⁹ The sensitivity of microscopy for detecting parasites in the

placenta is, however, much lower than that of polymerase chain reaction methods.¹¹⁰

The incidence of malaria episodes and the parasite density decrease with the number of pregnancies, and less excess malaria is observed with subsequent pregnancies.¹¹¹⁻¹¹⁵ In low-transmission areas, women of all gravidities are susceptible to symptomatic, severe maternal disease: miscarriage, stillbirth and congenital malaria are common complications, and malaria is an important cause of low birthweight.^{116,117}

Safety and efficacy of antimalarial agents in pregnant women

The choice of antimalarial drug for pregnant women depends on their tolerance and on the absence of toxicity. The choice should also take into account the period of pregnancy and local efficacy against *P. falciparum*

Chloroquine

Chloroquine has been widely used to treat *falciparum* malaria during pregnancy. In 1986, WHO recommended that pregnant women living in malaria-endemic areas receive chloroquine chemoprophylaxis.¹¹⁸ Subsequently, alarming evidence of resistance of the malaria parasite to this drug emerged. Steketee and colleagues¹¹⁹ reported a 42% treatment failure in Siaya District, Kenya, in 1986 and a 46% failure 10 years later.¹²⁰ In the United Republic of Tanzania

Table 1. Median prevalence of maternal malaria parasitaemia in peripheral blood during pregnancy in areas with stable transmission.

Study period	Country	Sample size	Prevalence (%)	References
2006-2008	Burkina Faso	1034	39.2	88
2010	Burkina Faso	579	18.1	89
1999-2001	Cameroon	770	32.8	90
2005-2006	Gabon	203	34.4	91
1992	Gambia	537	27%	92
2009	Ghana	363	28.4	93
1994-1996	Kenya	713	45	94
2002-2003	Malawi	1869	20.1	95
1996	Uganda	853	62.1	96
1994-1995	United Republic of Tanzania	1177	35.2	97
1993	United Republic of Tanzania	389	65.5	98
1989	Central African Republic	229	35.6	99

Table 2. Median prevalence of maternal malaria parasitaemia in peripheral blood during pregnancy in areas with low transmission.

Study period	Country	Sample size	Mode of transmission	Prevalence (%)	Reference
1998	Uganda	537	Meso-endemic	8.6	100
2003-2004	Sudan	836	Meso-endemic	26.2	101
2000	Ethiopia	1774	Seasonal	2.3	102
2001	Sudan	175	Seasonal	17.4	103
2003	Sudan	744	Seasonal	13.7	104

in 1991, treatment failed in 35% of 49 pregnant women.¹²¹ Curiously, chloroquine was reported to be 100% effective against *falciparum* malaria in a study in northern Nigeria in 1993.¹²² In Malawi, Heymann *et al.*¹²³ found that 37% of pregnant women failed to eliminate *P. falciparum* after 4 weeks of supervised chemoprophylaxis with chloroquine. In 1990, 37.1% of women in the Central African Republic had placental *P. falciparum* malaria, despite chemoprophylaxis.⁹⁹ In Benin, chemoprophylaxis with chloroquine for 7 months during pregnancy did not prevent placental parasitaemia in 12.7% of women.¹²⁴ A study in Burkina Faso of the efficacy of chloroquine and sulfadoxine-pyrimethamine (SP) for the prevention of malaria in pregnancy showed a placental parasitaemia prevalence of 18.8% and 10.6%, respectively.¹²⁵

Because of the increasing resistance of malaria parasites to chloroquine, WHO recommended in 2004 that SP be used as an alternative for the prevention of malaria during pregnancy.¹²⁶

Sulfadoxine-pyrimethamine

SP is used in pregnant women even though knowledge about its safety is limited. The only suspected form of toxicity is kernicterus with neurotoxicity due to unconjugated bilirubin. Sulphonamides can de-conjugate bilirubin bound to albumin, which would theoretically increase the risk for kernicterus if SP were administered during the third trimester of pregnancy.¹²⁷

Two studies indicate that the SP clears parasites within 48-72 h.¹²⁸ In Malawi, Schultz and colleagues¹²⁹ demonstrated that two curative doses of SP (one in the second trimester and a second in the third trimester) significantly reduced placental parasitaemia. WHO currently recommends intermittent preventive treatment in pregnancy (IPTp) with SP, with two curative doses 1 month apart from the second trimester of pregnancy, the first dose being given between weeks 14 and 20 and the second at least 1 month after the first.¹²⁶ More recently, WHO recommended that IPT be given at every antenatal clinic visit if the visits are at least 1 month apart.¹³⁰

Mefloquine

Mefloquine has a long half-life, making it useful for IPTp. In Malawi, administration of mefloquine in the second and third trimesters of pregnancy was effective, with good tolerance, although dizziness and abdominal pain were reported.¹³¹ In Benin, however, a clinical trial showed that two doses of 15 mg/kg mefloquine in the second and third trimesters, although significantly more effective than SP, were often accom-

panied by side-effects such as vomiting, dizziness and physical asthenia; a case of neuropsychiatric disorder was also noted.¹³²

Amodiaquine

Steketee and colleagues¹³³ observed a cure rate of 78% with amodiaquine among women who had parasitaemia under chloroquine chemoprophylaxis. The safety of amodiaquine in pregnancy and especially for the prevention of malaria is not documented.¹³⁴ The drug is considered to be well tolerated by pregnant women, but agranulocytosis, one of its serious side-effects, limits its use in prophylaxis.

Quinine

Quinine, which is considered to be well tolerated during pregnancy, is indicated only for curative treatment. The recommended doses must be respected to avoid abortive effects.¹³⁵⁻¹³⁹ Quinine has replaced chloroquine in the treatment of malaria in pregnant women, but few clinical trials have been conducted. Harmful effects of quinine during pregnancy have been recognized for a long time, and induction of uterine contractions has been reported.¹⁴⁰

A study of the safety and efficacy of quinine (30 mg/kg per day for 7 days) in Thailand showed side-effects such as dizziness in 42% of women,¹⁴¹ with 4% parasitaemia on day 7 of treatment and 23% resurgence of malaria on day 28 of clinical monitoring. A study of the efficacy of the combination of quinine and clindamycin in the second and third trimesters resulted in a 67% cure rate (95% confidence interval, 43-91%) by day 67 of clinical monitoring.¹⁴² A case of *P. falciparum* malaria resistant to quinine *in vivo* and *in vitro* was reported in 1988.¹⁴³ Hence, a combination of quinine (30 mg/kg per day) and clindamycin (15 mg/kg per day) for 7 days has been suggested for effective treatment of malaria.^{143,144}

Artemisinin derivatives

Artemisinin derivatives are generally well tolerated by pregnant women. Use of drug combinations such as artemether-lumefantrine in the second and third trimesters of pregnancy did not increase the risks for spontaneous abortion, stillbirth or congenital abnormalities when compared with quinine.¹⁴⁵ The PREGACT study group conducted a randomized, open-label trial between June 2010 through August 2013 to compare the safety and efficacy of artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine in Burkina Faso, Ghana, Malawi and Zambia in women in the second or third trimester of pregnancy. Artemether-lumefantrine was

associated with the fewest adverse effects and acceptable cure rates but provided the shortest post-treatment prophylaxis, while dihydroartemisinin-piperaquine was most effective and had an acceptable safety profile.¹⁴⁶

It has been suggested that artemether-lumefantrine is safe during the first trimester.¹⁴⁷ A study of birth outcomes of women inadvertently exposed to this combination during the first trimester found no adverse outcomes.¹⁴⁸ Because of insufficient data on the safety of these drugs during the first trimester of pregnancy, however, WHO recommends their use only during the second and third trimesters.¹²⁶

Dapsone and chlorproguanil

In a clinical trial in Uganda, minor side-effects (headache, nausea, sub-jaundice) were reported after use of dapsone-chlorproguanil during pregnancy.¹⁴⁹ A case of hyperbilirubinaemia due to dapsone administered to a pregnant woman for leprosy was reported.¹⁵⁰ Proguanil and chlorproguanil are well tolerated during pregnancy and have been recommended for prophylaxis against malaria for more than 40 years. Nevertheless, studies of pharmacokinetics showed altered metabolism of proguanil in pregnancy, suggesting that the dose should be increased for pregnant women,¹⁵¹⁻¹⁵³ which poses a problem of adjustment in the combination with dapsone. In Kenya, Keuter and colleagues¹⁵⁴ reported that a single dose of chlorproguanil (1.2 mg/kg) in combination with dapsone (2.4 mg/kg) was more effective and better tolerated than chloroquine.

The combination of dapsone with pyrimethamine was well tolerated by both the mother and the foetus during pregnancy, with good efficacy against malaria infection.¹⁵⁵⁻¹⁵⁸

Atovaquone-proguanil

Atovaquone, usually used to treat *Pneumocystis carinii* infections, has not been studied for tolerance during pregnancy. McGready and colleagues¹⁵² reported low plasma concentrations during pregnancy (almost two thirds less than in non-pregnant women) of atovaquone and proguanil, which are used in combination for the treatment of malaria. Use of this combination is still limited because of rapid selection of mutants resistant to atovaquone due to mutations of the cytochrome-b gene of *P. falciparum*.¹⁵⁹⁻¹⁶¹

Malaria prevention during pregnancy

Since 1980, African countries in which malaria transmission is stable have opted for chemoprophylaxis of malaria during

pregnancy with chloroquine.¹¹⁸ The first cases of resistance of *P. falciparum* to chloroquine were reported in Africa in 1980, and cases emerged in Asia during the 1980s. Given the reduced efficacy of chloroquine, many studies have been conducted to find an alternative for preventing malaria during pregnancy. SP has proved to be promising, as shown in many trials after the work of Schultz and colleagues in Malawi.¹²⁹ WHO recommends three strategies to prevent malaria in pregnant women living in endemic areas:¹²⁶ i) four antenatal care visits, during which at least two doses of SP spaced at least 1 month apart are administered in the second trimester of pregnancy; ii) use of insecticide-treated nets to reduce the number of infective bites; and iii) immediate, adequate treatment of malaria. IPTp involves administering curative doses of SP to asymptomatic women (two doses for women with negative HIV status and three doses for women infected with HIV), with at least 1 month between consecutive doses. Because of the risk of embryotoxicity with SP, it should be administered from week 16 of amenorrhoea or week 14 of pregnancy.¹²⁶ This schedule was updated by WHO in 2012 with the recommendation that IPTp be given at every antenatal clinic visit if the visits are at least 1 month apart.¹³⁰

IPTp with SP and use of mosquito nets impregnated with long-lasting insecticide significantly reduce the burden of malaria during pregnancy, and the interventions are cost-effective.¹⁶²⁻¹⁶⁸ IPTp with SP (25 mg sulfadoxine and 1.25 mg pyrimethamine per kg body weight) reduces the adverse effects of malaria on maternal and fetal health during pregnancy^{129,169-172} and can last up to 60 days in areas where *P. falciparum* strains are fully susceptible.^{173,174} IPTp clears the placenta of possible parasites (therapeutic effect) and prevent further infection (prophylactic effect).¹⁷⁵

Currently, the main obstacle to this strategy is the emergence and increasing frequency of resistance of *P. falciparum* to SP, already observed in many sub-Saharan African countries.¹⁷⁶⁻¹⁸³ The emergence of resistance is due to accumulation of point mutations in the genes encoding dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), two key enzymes in the metabolic chain of *P. falciparum*. Pyrimethamine and sulfadoxine inhibit DHFR and DHPS, respectively. The number of mutations is correlated with the level of resistance of *P. falciparum*, as shown *in vitro*. The triple mutant N51I/C59R/SN108 in the DHFR gene and the double

A437G/K540E mutant in the DHPS gene alone or in combination are associated with treatment failure with SP.¹⁸⁴ Therefore, changes in the level of resistance should be monitored by analysing these resistance markers,¹⁸⁵ with urgent research for alternatives for malaria prophylaxis during pregnancy. A study in Uganda showed that IPTp with dihydroartemisinin-piperazine resulted in a lower burden of malaria than did treatment with sulfadoxine-pyrimethamine.¹⁸⁶ The study suggested administration of dihydroartemisinin-piperazine every 4 weeks from as early as 16 weeks of gestation, which is in the line with the WHO recommendation.¹³⁰

Will vaccination against malaria in pregnancy become possible? An ideal vaccine should simulate all the protective responses that occur in natural infections. A good current candidate is the VAR2CSA antigen, the structure of which differs from that of other PfEMP1 antigens. Identification of a distinct PfEMP1 variant, VAR2CSA as the dominant surface antigen and a clinically important target for a protective immune response to malaria in pregnancy has raised hope.¹⁸⁷

The VAR2CSA gene displays significant polymorphism, as demonstrated by the number of possible unique antigens that have been produced; however, it is better conserved than other VAR genes, and VAR2CSA retains 75-83% of its amino acids between isolated strains.

Thus, a limited number of antigens is possible, although the degree of antigenic variation among globally isolated parasite lines has not been determined.¹⁸⁸ Research on a VAR2CSA-based vaccine includes mapping CSA-binding sites and antibody epitopes, defining Duffy binding-like domains preferentially recognized by immune sera and assessing functional activity by antibodies raised against recombinant Duffy binding-like domains.^{189,190} In 2014, the European Vaccine Initiative hosted a meeting to harmonize clinical development, immunoassays and standards to assess candidate vaccines against placental malaria. The panel concluded that early clinical trials should be conducted of VAR2CSA-based vaccine candidates in women in areas endemic for *P. falciparum* malaria before their first pregnancy.¹⁹¹ Currently, a VAR2CSA-based vaccine candidate, PAM-VAC, is being tested in Beninese women by an European Union funded multi-country consortium (PlacMalVac project, ClinicalTrials.gov Identifier: NCT02647489).¹⁹²

Co-infections with malaria during pregnancy: an emerging challenge for control

Co-infection with HIV

Co-infection with HIV increases susceptibility to malaria in pregnant women. Malaria and HIV both cause substantial morbidity and mortality, particularly in sub-Saharan Africa, and it has been estimated that an additional 500 000 malaria infections occur each year in pregnant women due to decreased immunity after HIV infection.¹⁹³ Concurrent HIV infection and malaria during pregnancy is a very serious problem for both maternal and child health.¹⁹⁴ Pregnant women infected with HIV are more likely to have malaria episodes,^{195,196} and the association has a synergistic effect, particularly on severe anaemia, to increase maternal mortality.^{197,198} Several studies (reviewed in¹⁹³) also show an increased prevalence of low birth weight (<2500 g), preterm delivery and intrauterine growth retardation in co-infected women. Co-infection with malaria is also associated with an increased HIV load, increasing the risk for mother-to-child transmission of HIV.^{199,200}

Concurrent management of malaria and HIV infection in pregnancy in sub-Saharan Africa is challenging. Medications against the two infections must be administered with caution because of interactions and overlapping toxicity (reviewed in²⁰¹). For example, co-administration of quinine and protease or non-nucleoside reverse transcriptase inhibitors can be cardiotoxic by inhibiting cytochrome P450 enzyme activity.²⁰²

HIV-positive women who are not taking co-trimoxazole prophylaxis for opportunistic infections can take a monthly dose of SP,²⁰³ which is significantly more effective than the two-dose regimen in these women and does not depend on the degree of SP resistance.^{170,203,204} Co-trimoxazole has been shown to decrease malaria morbidity in children and HIV-infected adults²⁰⁵⁻²⁰⁷ because it shares the same drug targets as SP and is hence effective against protozoan infections.²⁰⁸ The first report of the greater effectiveness of co-trimoxazole than IPTp with SP against malaria in HIV-infected pregnant women was published in 2011.²⁰⁹ In 2014, Denoed-Ndam *et al.*²¹⁰ showed that co-trimoxazole alone provided adequate protection against malaria in HIV-infected pregnant women. In light of the increasing prevalence of antifolate-resistant parasites,²¹¹ however, it is uncertain whether SP and co-trimoxazole will remain effective against malaria.

Infection with helminths with and without HIV

Emerging evidence during the past decade has implicated intestinal worm (helminth) infections as important causes of adverse pregnancy outcomes and impaired women's reproductive health (reviewed in ²¹²). Hookworms are important public health threats for women of reproductive age, and a recent study from Gabon reported a 66% prevalence of intestinal helminths in pregnant women.²¹³ In sub-Saharan Africa, hookworm infection is highly prevalent, with almost 99 million cases in women, 37.7 million among women of reproductive age and 6.9 million among pregnant women.^{214,215}

The worldwide distribution of helminths, malaria and HIV overlap.²¹⁶ Co-infection with helminths and malaria parasites cause significant morbidity in the host, particularly in the presence of HIV infection. Malaria in pregnancy due to *P. falciparum* and helminthic infections in HIV-infected pregnant women are severe public health problems. The prevalence of both malaria and helminths in HIV-infected pregnant women in Ruhuha province in Rwanda was estimated to be 10.1%.²¹⁷ A study in Kenya found that mother-to-child transmission of HIV was significantly higher when the women were co-infected with one or more helminths (48%) than in women with no helminth infection (10%; $P < 0.01$; adjusted odds ratio, 7.3; 95% confidence interval, 2.4-33.7).²¹⁸

Conclusions

Malaria is the commonest tropical parasite-transmitted disease during pregnancy, and, although the problem has been studied widely, there are still major challenges. Malaria infection during pregnancy requires rapid diagnosis and appropriate treatment to avoid complications for the woman and her foetus. Safe, new, effective antimalarial agents are urgently needed, in view of the growing resistance of *P. falciparum* to IPTp, as prophylactic chemotherapy is the main tool for controlling malaria during pregnancy. Special attention should be paid to the management of co-infection with HIV and with helminths, and studies of drug interactions between antiretroviral and antimalarial agents when co-administered in pregnancy are essential.

References

1. WHO: World Malaria Report 2016. Geneva: World Health Organization;

- 2016.
2. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM: Malaria. Lancet 2014;383:723-35.
3. Parekh FK, Hernandez JN, Krogstad DJ, et al. Prevalence and risk of Plasmodium falciparum and P. vivax malaria among pregnant women living in the hypoendemic communities of the Peruvian Amazon. Am J Trop Med Hyg 2007;77:451-7.
4. Takem EN, D'Alessandro U. Malaria in pregnancy. Med J Hematol Infect Dis 2013;5:e2013010.
5. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93-104.
6. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ 1983;61:1005-16.
7. Dellicour S, Tatem AJ, Guerra CA, et al. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 2010;7:e1000221.
8. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997;18:478-82.
9. Rogerson SJ, Hviid L, Duffy PE, et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007;7:105-17.
10. Duffy PE. Immunity to malaria during pregnancy: different host, different parasite. In: Duffy PE, Fried M, eds. Malaria in pregnancy deadly parasite, susceptible host. London: Taylor & Francis 2001. pp 70-126.
11. Miller LH, Baruch DI, Marsh K, Doumbo OK: The pathogenic basis of malaria. Nature 2002, 415:673-679.
12. Hedding A. Malaria pathogenesis: a jigsaw with an increasing number of pieces. Int J Parasitol 2002;32:1587-98.
13. Beeson JG, Amin N, Kanjala M, Rogerson SJ. Selective accumulation of mature asexual stages of Plasmodium falciparum-infected erythrocytes in the placenta. Infect Immun 2002;70:5412-5.
14. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996;272:1502-4.
15. Alsat E, Malassiné A, Tarade A, et al. Le Cytotrophoblaste humain, un casse-tête pour le biologiste. Médecine/Sciences 1999;15:1236-43.
16. Fox H. Pathology of the placenta: WB Saunders, 1997. p. 23.
17. Walter PR, Garin Y, Blot P. Placental pathologic changes in malaria. A histologic and ultrastructural study. Am J Pathol 1982;109:330-42.
18. Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 2000;31:85-93.
19. Rogerson SJ, Pollina E, Getachew A, et al. Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg 2003;68:115-9.
20. Ordi J, Ismail MR, Ventura PJ, et al. Massive chronic intervillitis of the placenta associated with malaria infection. Am J Surg Pathol 1998;22:1006-11.
21. Imamura T, Sugiyama T, Cuevas LE, et al. Expression of tissue factor, the clotting initiator, on macrophages in Plasmodium falciparum-infected placentas. J Infect Dis 2002;186:436-40.
22. Suguitan AL Jr., Leke RG, Fouda G, et al. Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis 2003;188:1074-82.
23. Chaisavaneeyakorn S, Moore JM, Mirel L, et al. Levels of macrophage inflammatory protein 1 alpha (MIP-1 alpha) and MIP-1 beta in intervillous blood plasma samples from women with placental malaria and human immunodeficiency virus infection. Clin Diagn Lab Immunol 2003;10:631-6.
24. Abrams ET, Brown H, Chensue SW, et al. Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated beta chemokine expression. J Immunol 2003;170:2759-64.
25. Lyall F. Priming and remodelling of human placental bed spiral arteries during pregnancy - a review. Placenta 2005;26:S31-6.
26. Rogerson SJ, Hviid L, Duffy PE, et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007;7:105-17.
27. Zamudio S. The Placenta at high altitude. High Alt Med Biol 2003, 4:171-191.
28. Soleymanlou N, Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005;90:4299-408.
29. Zamudio S. The placenta at high altitude. High Alt Med Biol 2003;4:171-91.
30. Kingdom JCP, Kaufmann P. Oxygen ad

- placental villous development: origins of fetal hypoxia. *Placenta* 1997;18:613.
31. Giudice LC. Insulin-like growth factor family in Graafian follicle development and function. *J Soc Gynecol Investig* 2001;8:S26-29.
 32. Regnault TR, de Vrijer B, Battaglia FC. Transport and metabolism of amino acids in placenta. *Endocrine* 2002;19:23-41.
 33. Zamudio S, Baumann MU, Illsley NP. Effects of chronic hypoxia in vivo on the expression of human placental glucose transporters. *Placenta* 2006;27:49-55.
 34. Tazuke SI, Mazure NM, Sugawara J, et al. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. *Proc Natl Acad Sci U S A* 1998;95:10188-93.
 35. Rogerson SJ, Mkundika P, Kanjala MK. Diagnosis of *Plasmodium falciparum* malaria at delivery: comparison of blood film preparation methods and of blood films with histology. *J Clin Microbiol* 2003;41:1370-4.
 36. Brabin B. An analysis of malaria in pregnancy in Africa. *Bull World Health Organ* 1983;61:1005-16.
 37. Hviid L. [Pregnancy-associated malaria]. *Med Trop* 2006;66:130-2.
 38. Brabin L. Parasitic infections in women and their consequences. *Adv Parasitol* 1992;31:1-81.
 39. Nielsen MA, Staalsoe T, Kurtzhals JA, et al. *Plasmodium falciparum* variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. *J Immunol* 2002;168:3444-50.
 40. Bull PC, Lowe BS, Kortok M, et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. *Nat Med* 1998;4:358-60.
 41. Bull P, Lowe B, Kortok M, et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. *Nat Med* 1998;4:358-60.
 42. Fried M, Nosten F, Brockman A, et al. Maternal antibodies block malaria. *Nature* 1998;395:851-2.
 43. Ricke CH, Staalsoe T, Koram K, et al. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on *Plasmodium falciparum*-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. *J Immunol* 2000;165:3309-16.
 44. Beeson JG, Rogerson SJ, Cooke BM, et al. Adhesion of *Plasmodium falciparum*-infected erythrocytes to hyaluronic acid in placental malaria. *Nat Med* 2000;6:86-90.
 45. Rasti N, Namusoke F, Chene A, et al. Nonimmune immunoglobulin binding and multiple adhesion characterize *Plasmodium falciparum*-infected erythrocytes of placental origin. *Proc Natl Acad Sci U S A* 2006;103:13795-800.
 46. Fried M, Domingo GJ, Gowda CD, et al. *Plasmodium falciparum*: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. *Exp Parasitol* 2006;113:36-42.
 47. Beeson JG, Rogerson SJ, Cooke BM, et al. Adhesion of *Plasmodium falciparum*-infected erythrocytes to hyaluronic acid in placental malaria. *Nat Med* 2000;6:86-90.
 48. Kane EG, Taylor-Robinson AW. Prospects and pitfalls of pregnancy-associated malaria vaccination based on the natural immune response to *Plasmodium falciparum* VAR2CSA-expressing parasites. *Malaria Res Treat* 2011;2011:764845.
 49. Salanti A, Dahlback M, Turner L, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. *J Exp Med* 2004;200:1197-203.
 50. Tuikue Ndam NG, Salanti A, Bertin G, et al. High level of var2csa transcription by *Plasmodium falciparum* isolated from the placenta. *J Infect Dis* 2005;192:331-5.
 51. Beeson JG, Brown GV, Molyneux ME, et al. *Plasmodium falciparum* isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. *J Infect Dis* 1999;180:464-72.
 52. Duffy PE, Fried M. Antibodies that inhibit *Plasmodium falciparum* adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. *Infect Immun* 2003;71:6620-3.
 53. Staalsoe T, Shulman CE, Bulmer JN, et al. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated *Plasmodium falciparum* malaria. *Lancet* 2004;363:283-9.
 54. Beeson JG, Mann EJ, Elliott SR, et al. Antibodies to variant surface antigens of *Plasmodium falciparum*-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. *J Infect Dis* 2004;189:540-51.
 55. Staalsoe T, Megnekou R, Fievet N, et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of *Plasmodium falciparum*-infected erythrocytes that protect against placental parasitemia. *J Infect Dis* 2001;184:618-26.
 56. O'Neil-Dunne I, Achur RN, Agbor-Enoh ST, et al. Gravidity-dependent production of antibodies that inhibit binding of *Plasmodium falciparum*-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. *Infect Immunity* 2001;69:7487-92.
 57. Bouyou-Akotet MK, Adegnika AA, Agnandji ST, et al. Cortisol and susceptibility to malaria during pregnancy. *Microbes Infect* 2005;7:1217-23.
 58. Vleugels MP, Brabin B, Eling WM, de Graaf R. Cortisol and *Plasmodium falciparum* infection in pregnant women in Kenya. *Trans R Soc Trop Med Hygiene* 1989;83:173-7.
 59. Rasheed FN, Bulmer JN, Dunn DT, et al. Suppressed peripheral and placental blood lymphoproliferative responses in first pregnancies: relevance to malaria. *Am J Trop Med Hyg* 1993;48:154-60.
 60. Vleugels MP, Eling WM, Rolland R, de Graaf R. Cortisol and loss of malaria immunity in human pregnancy. *Br J Obstet Gynaecol* 1987;94:758-64.
 61. Weinberg ED. Pregnancy-associated depression of cell-mediated immunity. *Rev Infect Dis* 1984;6:814-31.
 62. Okoko BJ, Enwere G, Ota MO. The epidemiology and consequences of maternal malaria: a review of immunological basis. *Acta Tropica* 2003;87:193-205.
 63. Riley EM, Schneider G, Sambou I, Greenwood BM. Suppression of cell-mediated immune responses to malaria antigens in pregnant Gambian women. *Am J Trop Med Hyg* 1989;40:141-4.
 64. Hviid L. Naturally acquired immunity to *Plasmodium falciparum* malaria in Africa. *Acta Trop* 2005;95:270-5.
 65. McGregor IA. Epidemiology, malaria and pregnancy. *Am J Trop Med Hyg* 1984;33:517-25.
 66. Brabin B. An analysis of malaria in pregnancy in Africa. *Bull World Health Organ* 1983;61:1005-16.
 67. Blacklock DB, Gordon RM. Malaria infection as it occurs in late pregnancy, its relationship to labour and early infancy. *Ann Trop Med Parasitol* 1925;19:327-65.
 68. Wickramasuriya GAW. Some observations on malaria occurring in associa-

- tion with pregnancy *J Obstet Gynaecol Br Empire* 1935;42:816-34.
69. Archibald HM. The influence of malarial infection of the placenta on the incidence of prematurity. *Bull World Health Organ* 1956;15:842-5.
 70. Cannon DS. Malaria and prematurity in the western region of Nigeria. *Br Med J* 1958;2:877-8.
 71. Gilles HM, Lawson JB, Sibelas M, et al. Malaria, anaemia and pregnancy. *Ann Trop Med Parasitol* 1969;63:245-63.
 72. Jelliffe EF. Low birth-weight and malarial infection of the placenta *Bull World Health Organ* 1968;38:69-78.
 73. Reinhardt MC, Ambroise-Thomas P, Cavallo-Serra R, et al. Malaria at delivery in Abidjan. *Helv Paediatr Acta* 1978;41:65-84.
 74. Spitz AJ. Malaria infection of the placenta and its influence on the incidence of prematurity in eastern Nigeria. *Bull World Health Organ* 1959;21:242-4.
 75. Bourée P, Bisaroa F, Couzigoub C. Paludisme et grossesse. *Revue Francophone des Laboratoires* 2008. p 402.
 76. WHO: Malaria in pregnancy. Guidelines for measuring key monitoring and evaluation indicators Geneva: WHO; 2007.
 77. Koller O. The clinical significance of hemodilution during pregnancy. *Obstet Gynecol Surv* 1982;37:649-52.
 78. Miller KL, Carlino JA, Ogawa Y, et al. Alterations in erythropoiesis in TGF-beta 1-treated mice. *Exp Hematol* 1992;20:951-6.
 79. Miller KL, Schooley JC, Smith KL, et al. Inhibition of erythropoiesis by a soluble factor in murine malaria. *Exp Hematol* 1989;17:379-85.
 80. Yap GS, Stevenson MM. Production of soluble inhibitor of erythropoiesis during *Plasmodium chabaudi* AS infection in resistant and susceptible mice. *Ann N Y Acad Sci* 1991;628:279-81.
 81. McDevitt MA, Xie J, Shanmugasundaram G, et al. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. *J Exp Med* 2006;203:1185-96.
 82. Chaiyaroj SC, Rutta AS, Muenthaisong K, et al. Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. *Acta Tropica* 2004;89:319-27.
 83. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. *Clin Microbiol Rev* 2004;17:760-9.
 84. Steketee RW, Wirima JJ, Hightower AW, et al. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. *Am J Trop Med Hyg* 1996;55:33-41.
 85. Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. *J Infect Dis* 2000;181:1740-5.
 86. Tako EA, Zhou A, Lohoue J, et al. Risk factors for placental malaria and its effect on pregnancy outcome in Yaounde, Cameroon. *Am J Trop Med Hyg* 2005;72:236-42.
 87. Sullivan AD, Nyirenda T, Cullinan T, et al. Malaria infection during pregnancy: intrauterine growth retardation and preterm delivery in Malawi. *J Infect Dis* 1999;179:1580-3.
 88. Valea I, Tinto H, Drabo MK, et al. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. *Malaria J* 2012;11:71.
 89. Cisse M, Sangare I, Lougue G, et al. Prevalence and risk factors for *Plasmodium falciparum* malaria in pregnant women attending antenatal clinic in Bobo-Dioulasso (Burkina Faso). *BMC Infect Dis* 2014;14:631.
 90. Akum AE, Kuoh AJ, Minang JT, et al. The effect of maternal, umbilical cord and placental malaria parasitaemia on the birthweight of newborns from South-western Cameroon. *Acta Paediatr* 2005;94:917-23.
 91. Bouyou-Akotet MK, Nzenze-Afene S, Ngoungou EB, et al. Burden of malaria during pregnancy at the time of IPTp/SP implementation in Gabon. *Am J Trop Med Hyg* 2010;82:202-9.
 92. D'Alessandro U, Langerock P, Bennett S, et al. The impact of a national impregnated bed net programme on the outcome of pregnancy in primigravidae in The Gambia. *Trans R Soc Trop Med Hyg* 1996;90:487-92.
 93. Wilson NO, Ceesay FK, Obed SA, et al. Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant women. *Am J Trop Med Hyg* 2011;85:12-21.
 94. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. *Am J Trop Med Hyg* 1998;59:813-22.
 95. Kalilani L, Mofolo I, Chaponda M, et al. The effect of timing and frequency of *Plasmodium falciparum* infection during pregnancy on the risk of low birth weight and maternal anemia. *Trans R Soc Trop Med Hyg* 2010;104:416-22.
 96. Ndyomugenyi R, Magnussen P. Anaemia in pregnancy: *Plasmodium falciparum* infection is an important cause in primigravidae in Hoima district, western Uganda. *Ann Trop Med Parasitol* 1999;93:457-65.
 97. Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. *J Infect Dis* 2000;181:1740-5.
 98. Matteelli A, Donato F, Shein A, et al. Malarial infection and birthweight in urban Zanzibar, Tanzania. *Ann Trop Med Parasitol* 1996;90:125-34.
 99. Testa J, Awodabon J, Lagarde N, et al. [Interest in placental apposition as an epidemiological marker for malaria]. *Bull Soc Pathol Exot* 1991;84:473-9.
 100. Kasumba IN, Nalunkuma AJ, Mujuzi G, et al. Low birthweight associated with maternal anaemia and *Plasmodium falciparum* infection during pregnancy, in a peri-urban/urban area of low endemicity in Uganda. *Ann Trop Med Parasitol* 2000;94:7-13.
 101. Omer S, Khalil E, Ali H, Sharief A. Submicroscopic and multiple *plasmodium falciparum* infections in pregnant Sudanese women. *N Am J Med Sci* 2011;3:137-41.
 102. Newman RD, Hailemariam A, Jimma D, et al. Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a non-epidemic year. *J Infect Dis* 2003;187:1765-72.
 103. Elghazali G, Adam I, Hamad A, El-Bashir MI. *Plasmodium falciparum* infection during pregnancy in an unstable transmission area in eastern Sudan. *East Mediterr Health J* 2003;9:570-80.
 104. Adam I, Khamis AH, Elbashir MI. Prevalence and risk factors for anaemia in pregnant women of eastern Sudan. *Trans R Soc Trop Med Hyg* 2005;99:739-43.
 105. Steketee RW, Breman JG, Paluku KM, et al. Malaria infection in pregnant women in Zaire: the effects and the potential for intervention. *Ann Trop Med Parasitol* 1988;82:113-20.
 106. Coulibaly SO, Gies S, D'Alessandro U. Malaria burden among pregnant women living in the rural district of Boromo, Burkina Faso. *Am J Trop Med Hyg* 2007;77:56-60.

107. Mutabingwa TK. Malaria and pregnancy: epidemiology, pathophysiology and control options. *Acta Tropica* 1994;57:239-54.
108. Testa J, Awodabon J, Lagarde N, et al. [Plasmodial indices and malarial placental pathology in 299 parturients in Central Africa]. *Med Trop* 1990;50:85-90.
109. Brabin BJ, Rogerson S. The epidemiology and outcomes of maternal malaria. In: Duffy PE, Fried M, eds. *Malaria in pregnancy, deadly parasites, susceptible host*. London: Taylor and Francis. 2001: p. 27-52.
110. Schleiermacher D, Le Hesran JY, Ndiaye JL, et al. Hidden *Plasmodium falciparum* parasites in human infections: different genotype distribution in the peripheral circulation and in the placenta. *Infect Genet Evol* 2002;2:97-105.
111. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. *Am J Trop Med Hyg* 1996;55:24-32.
112. Ofori M, Ansah E, Agyepong I, et al. Pregnancy-associated malaria in a rural community of Ghana. *Ghana Med J* 2009;43:13-8.
113. Nnaji GA, Okafor CI, Ikechebelu JI. An evaluation of the effect of parity and age on malaria parasitaemia in pregnancy. *J Obstet Gynaecol* 2006;26:755-8.
114. Diagne N, Rogier C, Cisse B, Trape JF. Incidence of clinical malaria in pregnant women exposed to intense perennial transmission. *Trans R Soc Trop Med Hyg* 1997;91:166-70.
115. Schleiermacher D, Rogier C, Spiegel A, et al. Increased multiplicity of *Plasmodium falciparum* infections and skewed distribution of individual *msp1* and *msp2* alleles during pregnancy in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. *Am J Trop Med Hyg* 2001;64:303-9.
116. Nosten F, ter Kuile F, Maelankirri L, et al. Malaria during pregnancy in an area of unstable endemicity. *Trans R Soc Trop Med Hyg* 1991;85:424-9.
117. Nosten F, Rogerson SJ, Beeson JG, et al. Malaria in pregnancy and the endemicity spectrum: what can we learn? *Trends Parasitol* 2004;20:425-32.
118. WHO: WHO Expert Committee on Malaria, 18th Report. *World Health Organ Tech Rep Ser* 1986. 735.
119. Steketee RW, Brandling-Bennett AD, Kaseje DC, et al. In vivo response of *Plasmodium falciparum* to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya. *Bull World Health Organ* 1987;65:885-80.
120. Rukaria-Kaumbutho RM, Ojwang SB, Oyieke JB. Resistance to chloroquine therapy in pregnant women with malaria parasitemia. *Int J Gynaecol Obstet* 1996;53:235-41.
121. Mutabingwa TK, Malle LN, Mtui SN: Chloroquine therapy still useful in the management of malaria during pregnancy in Muheza, Tanzania. *Trop Geogr Med* 1991;43:131-5.
122. Okoyeh JN, Lege-Oguntoye L, Emembolu JO, et al. Sensitivity of *Plasmodium falciparum* to chloroquine in pregnant women in Zaria, northern Nigeria. *Trop Geogr Med* 1993;45:56-8.
123. Heymann DL, Steketee RW, Wirima JJ, et al. Antenatal chloroquine chemoprophylaxis in Malawi: chloroquine resistance, compliance, protective efficacy and cost. *Trans R Soc Trop Med Hyg* 1990;84:496-8.
124. Denoed L, Fievet N, Aubouy A, et al. Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin. *Mal J* 2007;6:27.
125. Tiono AB, Ouedraogo A, Bougouma EC, et al. Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens. *Mal J* 2009;8:224.
126. WHO: A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. *AFR/MAL/04/01*; Regional Office for African, Brazzaville, Congo 2004.
127. WHO. Severe and complicated malaria. *Trans R Soc Trop Med Hyg* 1990;84.
128. Sowunmi A, Akindele JA, Omitowoju GO, et al. Intramuscular sulfadoxine-pyrimethamine in uncomplicated chloroquine-resistant *falciparum* malaria during pregnancy. *Trans R Soc Trop Med Hyg* 1993;87:472.
129. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental *Plasmodium falciparum* infection among pregnant women in Malawi. *Am J Trop Med Hyg* 1994;51:515-22.
130. WHO. Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxinepyrimethamine (IPTp-SP). Geneva: World Health Organization, 2012 (http://www.who.int/malaria/publications/atoz/who_iptp_sp_policy_recommendation/en/). 2012.
131. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. *Am J Trop Med Hyg* 1996;55:50-6.
132. Briand V, Bottero J, Noel H, et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. *J Infect Dis* 2009;200:991-1001.
133. Steketee RW, Brandling-Bennett AD, Kaseje DC, et al. In vivo response of *Plasmodium falciparum* to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya. *Bull World Health Organ* 1987;65:885-90.
134. Thomas F, Erhart A, D'Alessandro U. Can amodiaquine be used safely during pregnancy? *Lancet Infect Dis* 2004;4:235-9.
135. Smith JP. Risky choices: the dangers of teens using self-induced abortion attempts. *J Pediatr Health Care* 1998;12:147-51.
136. McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. *Trans R Soc Trop Med Hyg* 2002;96:180-4.
137. Baragatti M, Fournet F, Henry MC, et al. Social and environmental malaria risk factors in urban areas of Ouagadougou, Burkina Faso. *Malaria J* 2009;8:13.
138. Lenz W. Malformations caused by drugs in pregnancy. *Am J Dis Child* 1960;112:99-106.
139. McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant *falciparum* malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2000;94:689-93.
140. Maxwell JP. The use of quinine during pregnancy, labour, and the puerperium. *Trans R Soc Trop Med Hyg* 1908;1:229-35.
141. McGready R, Cho T, Hkirijaroen L, et al. Quinine and mefloquine in the treatment of multidrug-resistant *Plasmodium falciparum* malaria in pregnancy. *Ann Trop Med Parasitol* 1998;92:643-53.
142. McGready R, Cho T, Samuel, et al. Randomized comparison of quinine-clindamycin versus artesunate in the

- treatment of falciparum malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2001;95:651-6.
143. Rolfe M. Multiple drug resistant *Plasmodium falciparum* malaria in a pregnant indigenous Zambian woman. *Trans R Soc Trop Med Hyg* 1988;82:554-7.
 144. Fripp PJ, Sieling WL. Clindamycin: a second line antimalarial agent. *S Afr Med J* 1987;72:647.
 145. Manyando C, Kayentao K, D'Alessandro U, et al. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated *Plasmodium falciparum* malaria during pregnancy. *Malaria J* 2012;11:141.
 146. Peki D, Ampromfi AA, Tinto H, et al. Four artemisinin-based treatments in African pregnant women with malaria. *Malawi Med J* 2016;28:139-49.
 147. Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. *Malaria J* 2010;9:249.
 148. Mosha D, Mazuguni F, Mrema S, et al. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. *Malaria J* 2014;13:197.
 149. Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. *J Infect Dev Countries* 2008;2:135-9.
 150. Thornton YS, Bowe ET. Neonatal hyperbilirubinemia after treatment of maternal leprosy. *South Med J* 1989;82:668.
 151. Wangboonskul J, White NJ, Nosten F, et al. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. *Eur J Clin Pharmacol* 1993;44:247-51.
 152. McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. *Eur J Clin Pharmacol* 2003;59:545-52.
 153. McGready R, Stepniewska K, Seaton E, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. *Eur J Clin Pharmacol* 2003;59:553-7.
 154. Keuter M, van Eijk A, Hoogstrate M, et al. Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya. *BMJ* 1990;301:466-70.
 155. Greenwood BM, Greenwood AM, Snow RW, et al. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. *Trans R Soc Trop Med Hyg* 1989;83:589-94.
 156. Greenwood AM, Armstrong JR, Byass P, et al. Malaria chemoprophylaxis, birth weight and child survival. *Trans R Soc Trop Med Hyg* 1992;86:483-5.
 157. Greenwood AM, Menendez C, Todd J, Greenwood BM. The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control women. *Trans R Soc Trop Med Hyg* 1994;88:311-2.
 158. Menendez C, Todd J, Alonso PL, et al. Malaria chemoprophylaxis, infection of the placenta and birth weight in Gambian primigravidae. *J Trop Med Hyg* 1994;97:244-8.
 159. Meshnick SR, Trumppower B. Multiple cytochrome B mutations may cause atovaquone resistance. *J Infect Dis* 2005;191:822-3.
 160. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant *Plasmodium falciparum* malaria acquired by a non-immune traveler to East Africa. *Clin Infect Dis* 2003;37:450-1.
 161. Gil JP, Nogueira F, Stromberg-Norklit J, et al. Detection of atovaquone and Malarone resistance conferring mutations in *Plasmodium falciparum* cytochrome b gene (cytb). *Mol Cell probes* 2003;17:85-9.
 162. Rogier C. Challenge of developing anti-parasite vaccines in the tropics. *Med Trop* 2007;67:328-34.
 163. Briand V, Denoel L, Massougbojji A, Cot M. Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. *J Infect Dis* 2008;198:594-601.
 164. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. *Trop Med Int Health* 2004;9:351-60.
 165. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. *Trans R Soc Trop Med Hyg* 2008;102:685-93.
 166. Schultz LJ, Steketee RW, Chitsulo L, Wirima JJ. Antimalarials during pregnancy: a cost-effectiveness analysis. *Bull World Health Organ* 1995;73:207-14.
 167. Sicuri E, Bardaji A, Nhampossa T, et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. *PLoS One* 2010;5:e13407.
 168. Wolfe EB, Parise ME, Haddix AC, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. *Am J Trop Med Hyg* 2001;64:178-86.
 169. Verhoeff FH, Brabin BJ, Chimsuku L, et al. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. *Ann Trop Med Parasitol* 1998;92:141-50.
 170. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. *Am J Trop Med Hyg* 1998;59:813-22.
 171. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. *Lancet* 1999;353:632-6.
 172. Rogerson SJ, Chaluluka E, Kanjala M, et al. Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99. *Trans R Soc Trop Med Hyg* 2000;94:549-53.
 173. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. More on the efficacy of antifolates antimalarial combinations in Africa. *Parasitol Today* 1999;15:131-2.
 174. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents Chemother* 1997;41:1413-22.
 175. White NJ. Intermittent presumptive treatment for malaria. *PLoS Med* 2005;2:e3.
 176. Ronn AM, Msangeni HA, Mhina J, et al. High level of resistance of *Plasmodium falciparum* to sulfadoxine-pyrimethamine in children in Tanzania. *Trans R Soc Trop Med Hyg* 1996;90:179-81.
 177. Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarial resistance in southeast Africa: a population-based

- analysis. *Lancet* 2003;361:1174-81.
178. Menard D, Djalle D, Manirakiza A, et al. Drug-resistant malaria in Bangui, Central African Republic: an in vitro assessment. *Am J Trop Med Hyg* 2005;73:239-43.
 179. Menard D, Djalle D, Yapou F, et al. Frequency distribution of antimalarial drug-resistant alleles among isolates of *Plasmodium falciparum* in Bangui, Central African Republic. *Am J Trop Med Hyg* 2006;74:205-10.
 180. Raman J, Little F, Roper C, et al. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. *Am J Trop Med Hyg* 2010;82:788-94.
 181. Gesase S, Gosling RD, Hashim R, et al. High resistance of *Plasmodium falciparum* to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. *PLoS One* 2009;4:e4569.
 182. Mombo-Ngoma G, Oyakhrome S, Ord R, et al. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. *Malaria J* 2011;10:123.
 183. Ndiaye D, Dieye B, Ndiaye YD, et al. Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in *Plasmodium falciparum* malaria parasites in Thies, Senegal. *Int J Parasitol Drugs Drug Resist* 2013;3:135-42.
 184. Kublin JG, Dzinjalama FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis* 2002;185:380-8.
 185. Deloron P, Bertin G, Briand V, et al. Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. *Emerg Infect Dis* 2010;16:1666-70.
 186. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-piperazine for the prevention of malaria in pregnancy. *New Engl J Med* 2016;374:928-39.
 187. Tuikue Ndam N, Deloron P. Towards a vaccine against pregnancy-associated malaria. *Parasite* 2008;15:515-21.
 188. Bockhorst J, Lu F, Janes JH, et al. Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. *Mol Biochem Parasitol* 2007;155:103-12.
 189. Bigey P, Gnidehou S, Doritchamou J, et al. The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several *Plasmodium falciparum* isolates to chondroitin sulfate A. *J Infect Dis* 2011;204:1125-33.
 190. Doritchamou J, Bigey P, Nielsen MA, et al. Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. *Vaccine* 2013;31:4516-22.
 191. Chene A, Houard S, Nielsen MA, et al. Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. *Malaria J* 2016;15:476.
 192. Gbedande K, Fievet N, Viwami F, et al. Clinical development of a VAR2CSA-based placental malaria vaccine PAM-VAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. *Vaccine* 2017;35:3474-81.
 193. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. *Am J Trop Med Hyg* 2004;71:41-54.
 194. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit *Plasmodium falciparum* by infection with human immunodeficiency virus type-1. *Am J Trop Med Hyg* 1996;55:42-9.
 195. van Eijk AM, Ayisi JG, ter Kuile FO, et al. HIV increases the risk of malaria in women of all gravities in Kisumu, Kenya. *Aids* 2003;17:595-603.
 196. Ticconi C, Mapfumo M, Dorrucchi M, et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. *J Acquir Immune Defic Syndr* 2003;34:289-94.
 197. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Human immunodeficiency virus seropositivity and malaria as risk factors for third-trimester anemia in asymptomatic pregnant women in western Kenya. *Am J Trop Med Hyg* 2001;65:623-30.
 198. Ayisi JG, van Eijk AM, ter Kuile FO, et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. *AIDS* 2003;17:585-94.
 199. Brahmabhatt H, Sullivan D, Kigozi G, et al. Association of HIV and malaria with mother-to-child transmission, birth outcomes, and child mortality. *J Acquir Immune Defic Syndr* 2008;47:472-6.
 200. Brahmabhatt H, Kigozi G, Wabwire-Mangen F, et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. *AIDS* 2003;17:2539-41.
 201. Brentlinger PE, Behrens CB, Micek MA. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. *Lancet Infect Dis* 2006;6:100-11.
 202. Khoo S, Back D, Winstanley P. The potential for interactions between anti-malarial and antiretroviral drugs. *AIDS* 2005;19:995-1005.
 203. Filler SJ, Kazembe P, Thigpen M, et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. *J Infect Dis* 2006;194:286-93.
 204. Meshnick SR, Mwapasa V, Rogerson SJ. Protecting pregnant women from malaria in areas of high HIV infection prevalence. *J Infect Dis* 2006;194:273-5.
 205. Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? *Am J Trop Med Hyg* 2008;79:320-30.
 206. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. *AIDS* 2007;21:2059-66.
 207. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on *falciparum* malaria infection and disease. *J Infect Dis* 2005;192:1823-9.
 208. Brumfitt W, Hamilton-Miller JM. Limitations of and indications for the use of co-trimoxazole. *J Chemother* 1994;6:3-11.
 209. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, et al. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. *J Infect Dis* 2011;203:464-72.
 210. Denoed-Ndam L, Zannou DM, Fourcade C, et al. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent

- malaria in HIV-infected pregnant women: two randomized controlled trials. *J Acquir Immune Defic Syndr* 2014;65:198-206.
211. Desai M, Gutman J, Taylor SM, et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. *Clin Infect Dis* 2016;62:323-33.
212. Hotez P, Whitham M. Helminth infections: a new global women's health agenda. *Obstet Gynecol* 2014;123:155-60.
213. Adegnik AA, Agnandji ST, Chai SK, et al. Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. *Wien Klin Wochenschr* 2007;119:712-6.
214. de Silva NR, Brooker S, Hotez PJ, et al. Soil-transmitted helminth infections: updating the global picture. *Trends Parasitol* 2003;19:547-51.
215. Brooker S, Hotez PJ, Bundy DA. Hookworm-related anaemia among pregnant women: a systematic review. *PLoS Neglect Trop Dis* 2008;2:e291.
216. Hotez PJ, Brindley PJ, Bethony JM, et al. Helminth infections: the great neglected tropical diseases. *J Clin Investigat* 2008;118:1311-21.
217. Ivan E, Crowther NJ, Rucogoza AT, et al. Malaria and helminthic co-infection among HIV-positive pregnant women: prevalence and effects of antiretroviral therapy. *Acta Tropica* 2012;124:179-84.
218. Gallagher M, Malhotra I, Mungai PL, et al. The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. *AIDS* 2005;19:1849-55.